Organic Solute Transporter, OSTα-OSTβ: Its Role in Bile Acid Transport and Cholestasis

 

 Buy Article Permissions and Reprints

ABSTRACT

Organic solute transporter alpha-beta (OSTα-OSTβ) is a unique heteromeric transporter localized to the basolateral membrane of epithelial cells involved in sterol transport. It is believed to be the primary bile acid efflux transporter in the intestine of mammals and is therefore essential to bile acid homeostasis and the enterohepatic circulation. First described in the evolutionarily primitive small skate, Leucoraja erinacea, this facilitated transporter requires expression of both subunits for its function. It can transport a variety of bile acids, as well as estrone 3-sulfate, dehydroepiandrosterone 3-sulfate, digoxin, and prostaglandin E₂. Expression of both subunits is variable between species and tissues; in humans high expression is noted in the liver, small intestine, kidney, testis, and adrenal gland. OSTα-OSTβ is directly regulated by the bile acid sensing nuclear receptor, farnesoid X receptor (FXR). Furthermore, it is part of the complex regulatory pathway that controls bile acid synthesis and homeostasis. Hepatic OSTα-OSTβ is upregulated in cholestasis in both humans and rodents, where it appears to play a protective role. Additional studies are necessary to determine its role in liver injury, bile acid malabsorption, and lipid and glucose metabolism, as well as a potential protective role for kidney OSTα-OSTβ in cholestasis.

REFERENCES

• 1 Wong M H, Oelkers P, Craddock A L, Dawson P A. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter.  J Biol Chem. 1994;  269(2) 1340-1347
  PubMedGoogle Scholar
• 2 Wang W, Seward D J, Li L, Boyer J L, Ballatori N. Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate.  Proc Natl Acad Sci U S A. 2001;  98(16) 9431-9436
  CrossrefPubMedGoogle Scholar
• 3 Seward D J, Koh A S, Boyer J L, Ballatori N. Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta.  J Biol Chem. 2003;  278(30) 27473-27482
  CrossrefPubMedGoogle Scholar
• 4 Rao A, Haywood J, Craddock A L, Belinsky M G, Kruh G D, Dawson P A. The organic solute transporter α-β, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis.  Proc Natl Acad Sci U S A. 2008;  105(10) 3891-3896
  CrossrefPubMedGoogle Scholar
• 5 Soroka C J, Mennone A, Hagey L, Ballatori N, Boyer J L. Organic solute transporter α deficiency enhances renal excretion of bile acids and attenuates cholestasis.  Hepatology. 2010;  51 181-190
  PubMedGoogle Scholar
• 6 Ballatori N, Christian W V, Lee J Y et al.. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia.  Hepatology. 2005;  42(6) 1270-1279
  CrossrefPubMedGoogle Scholar
• 7 Ballatori N, Li N, Fang F, Boyer J L, Christian W V, Hammond C L. OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids.  Front Biosci. 2009;  14 2829-2844
  PubMedGoogle Scholar
• 8 Balesaria S, Pell R J, Abbott L J et al.. Exploring possible mechanisms for primary bile acid malabsorption: evidence for different regulation of ileal bile acid transporter transcripts in chronic diarrhoea.  Eur J Gastroenterol Hepatol. 2008;  20(5) 413-422
  CrossrefPubMedGoogle Scholar
• 9 Lee H, Zhang Y, Lee F Y, Nelson S F, Gonzalez F J, Edwards P A. FXR regulates organic solute transporters α and β in the adrenal gland, kidney, and intestine.  J Lipid Res. 2006;  47(1) 201-214
  PubMedGoogle Scholar
• 10 Dawson P A, Hubbert M, Haywood J et al.. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter.  J Biol Chem. 2005;  280(8) 6960-6968
  CrossrefPubMedGoogle Scholar
• 11 Soroka C J, Xu S, Mennone A, Lam P, Boyer J L. N-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta.  BMC Cell Biol. 2008;  9 57
  CrossrefPubMedGoogle Scholar
• 12 Sun A-Q, Balasubramaniyan N, Xu K et al.. Protein-protein interactions and membrane localization of the human organic solute transporter.  Am J Physiol Gastrointest Liver Physiol. 2007;  292(6) G1586-G1593
  CrossrefPubMedGoogle Scholar
• 13 Li N, Cui Z, Fang F, Lee J Y, Ballatori N. Heterodimerization, trafficking and membrane topology of the two proteins, Ost α and Ost beta, that constitute the organic solute and steroid transporter.  Biochem J. 2007;  407(3) 363-372
  CrossrefPubMedGoogle Scholar
• 14 Boyer J L, Trauner M, Mennone A et al.. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents.  Am J Physiol Gastrointest Liver Physiol. 2006;  290(6) G1124-G1130
  CrossrefPubMedGoogle Scholar
• 15 Frankenberg T, Rao A, Chen F, Haywood J, Shneider B L, Dawson P A. Regulation of the mouse organic solute transporter α-β, Ostalpha-Ostbeta, by bile acids.  Am J Physiol Gastrointest Liver Physiol. 2006;  290(5) G912-G922
  PubMedGoogle Scholar
• 16 Landrier J-F, Eloranta J J, Vavricka S R, Kullak-Ublick G A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes.  Am J Physiol Gastrointest Liver Physiol. 2006;  290(3) G476-G485
  CrossrefPubMedGoogle Scholar
• 17 Lu T T, Makishima M, Repa J J et al.. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors.  Mol Cell. 2000;  6(3) 507-515
  CrossrefPubMedGoogle Scholar
• 18 Denson L A, Sturm E, Echevarria W et al.. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp.  Gastroenterology. 2001;  121(1) 140-147
  CrossrefPubMedGoogle Scholar
• 19 Sinal C J, Tohkin M, Miyata M, Ward J M, Lambert G, Gonzalez F J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.  Cell. 2000;  102(6) 731-744
  CrossrefPubMedGoogle Scholar
• 20 Grober J, Zaghini I, Fujii H et al.. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer.  J Biol Chem. 1999;  274(42) 29749-29754
  CrossrefPubMedGoogle Scholar
• 21 Zollner G, Wagner M, Moustafa T et al.. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-α/β in the adaptive response to bile acids.  Am J Physiol Gastrointest Liver Physiol. 2006;  290(5) G923-G932
  PubMedGoogle Scholar
• 22 Ballatori N, Fang F, Christian W V, Li N, Hammond C L. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver.  Am J Physiol Gastrointest Liver Physiol. 2008;  295(1) G179-G186
  CrossrefPubMedGoogle Scholar
• 23 Inagaki T, Choi M, Moschetta A et al.. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.  Cell Metab. 2005;  2(4) 217-225
  CrossrefPubMedGoogle Scholar
• 24 Boyer J L. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.  J Hepatol. 2007;  46(3) 365-371
  CrossrefPubMedGoogle Scholar
• 25 Zollner G, Fickert P, Silbert D et al.. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.  J Hepatol. 2003;  38(6) 717-727
  CrossrefPubMedGoogle Scholar
• 26 Schaap F G, van der Gaag N A, Gouma D J, Jansen P LM. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.  Hepatology. 2009;  49(4) 1228-1235
  CrossrefPubMedGoogle Scholar
• 27 Keitel V, Burdelski M, Warskulat U et al.. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.  Hepatology. 2005;  41(5) 1160-1172
  CrossrefPubMedGoogle Scholar
• 28 Chen J, Terada T, Ogasawara K, Katsura T, Inui K-i. Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis.  Am J Physiol Renal Physiol. 2008;  295(1) F247-F252
  CrossrefPubMedGoogle Scholar
• 29 Zollner G, Wagner M, Fickert P et al.. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis.  Liver Int. 2007;  27(7) 920-929
  CrossrefPubMedGoogle Scholar
• 30 Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).  J Biol Chem. 2000;  275(4) 2905-2910
  CrossrefPubMedGoogle Scholar
• 31 Zamek-Gliszczynski M J, Nezasa K-i, Tian X et al.. Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice.  J Pharmacol Exp Ther. 2006;  319(3) 1485-1491
  CrossrefPubMedGoogle Scholar
• 32 Cui Y J, Aleksunes L M, Tanaka Y, Goedken M J, Klaassen C D. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice.  Toxicol Sci. 2009;  110(1) 47-60
  CrossrefPubMedGoogle Scholar
• 33 Donner M G, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver.  Hepatology. 2001;  34(2) 351-359
  CrossrefPubMedGoogle Scholar
• 34 Ogawa K, Suzuki H, Hirohashi T et al.. Characterization of inducible nature of MRP3 in rat liver.  Am J Physiol Gastrointest Liver Physiol. 2000;  278(3) G438-G446
  PubMedGoogle Scholar
• 35 Soroka C J, Lee J M, Azzaroli F, Boyer J L. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver.  Hepatology. 2001;  33(4) 783-791
  CrossrefPubMedGoogle Scholar
• 36 Belinsky M G, Dawson P A, Shchaveleva I et al.. Analysis of the in vivo functions of Mrp3.  Mol Pharmacol. 2005;  68(1) 160-168
  PubMedGoogle Scholar
• 37 Bohan A, Chen W-S, Denson L A, Held M A, Boyer J L. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis.  J Biol Chem. 2003;  278(38) 36688-36698
  CrossrefPubMedGoogle Scholar
• 38 Zelcer N, van de Wetering K, de Waart R et al.. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides.  J Hepatol. 2006;  44(4) 768-775
  CrossrefPubMedGoogle Scholar
• 39 König J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane.  Hepatology. 1999;  29(4) 1156-1163
  CrossrefPubMedGoogle Scholar
• 40 Kruh G D, Belinsky M G, Gallo J M, Lee K. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice.  Cancer Metastasis Rev. 2007;  26(1) 5-14
  CrossrefPubMedGoogle Scholar
• 41 Mennone A, Soroka C J, Cai S-Y et al.. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis.  Hepatology. 2006;  43(5) 1013-1021
  CrossrefPubMedGoogle Scholar
• 42 Assem M, Schuetz E G, Leggas M et al.. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice.  J Biol Chem. 2004;  279(21) 22250-22257
  CrossrefPubMedGoogle Scholar
• 43 Saini S PS, Sonoda J, Xu L et al.. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification.  Mol Pharmacol. 2004;  65(2) 292-300
  CrossrefPubMedGoogle Scholar
• 44 Wagner M, Halilbasic E, Marschall H-U et al.. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.  Hepatology. 2005;  42(2) 420-430
  CrossrefPubMedGoogle Scholar
• 45 Stedman C AM, Liddle C, Coulter S A et al.. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury.  Proc Natl Acad Sci U S A. 2005;  102(6) 2063-2068
  CrossrefPubMedGoogle Scholar
• 46 Huang W, Zhang J, Moore D D. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR.  J Clin Invest. 2004;  113(1) 137-143
  CrossrefPubMedGoogle Scholar
• 47 Yin J, Wennberg R P, Xia Y C, Liu J W, Zhou H Z. Effect of a traditional Chinese medicine, yin zhi huang, on bilirubin clearance and conjugation.  Dev Pharmacol Ther. 1991;  16(1) 59-64
  PubMedGoogle Scholar
• 48 Modica S, Bellafante E, Moschetta A. Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio.  Front Biosci. 2009;  14 4719-4745
  PubMedGoogle Scholar
• 49 Bloomer J R, Boyer J L. Phenobarbital effects in cholestatic liver diseases.  Ann Intern Med. 1975;  82(3) 310-317
  CrossrefPubMedGoogle Scholar
• 50 Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials.  Liver Int. 2006;  26(8) 943-948
  CrossrefPubMedGoogle Scholar
• 51 Schlattjan J H, Winter C, Greven J. Regulation of renal tubular bile acid transport in the early phase of an obstructive cholestasis in the rat.  Nephron Physiol. 2003;  95(3) 49-56
  CrossrefPubMedGoogle Scholar
• 52 Stiehl A, Raedsch R, Rudolph G, Gundert-Remy U, Senn M. Biliary and urinary excretion of sulfated, glucuronidated and tetrahydroxylated bile acids in cirrhotic patients.  Hepatology. 1985;  5(3) 492-495
  CrossrefPubMedGoogle Scholar
• 53 Knisely A S, Strautnieks S S, Meier Y et al.. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency.  Hepatology. 2006;  44(2) 478-486
  CrossrefPubMedGoogle Scholar
• 54 Halpern M D, Dvorak B. Does abnormal bile acid metabolism contribute to NEC?.  Semin Perinatol. 2008;  32(2) 114-121
  CrossrefPubMedGoogle Scholar
• 55 Renner O, Harsch S, Strohmeyer A, Schimmel S, Stange E F. Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease.  J Lipid Res. 2008;  49(9) 2045-2054
  CrossrefPubMedGoogle Scholar
• 56 Kakizaki S, Yamazaki Y, Takizawa D, Negishi M. New insights on the xenobiotic-sensing nuclear receptors in liver diseases—CAR and PXR—.  Curr Drug Metab. 2008;  9(7) 614-621
  CrossrefPubMedGoogle Scholar
• 57 Rezen T, Tamasi V, Lövgren-Sandblom A, Björkhem I, Meyer U A, Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers.  BMC Genomics. 2009;  10 384
  CrossrefPubMedGoogle Scholar
• 58 Stefano F, Sabrina C, Baldelli F, Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.  Prog Lipid Res. 2009;  49(2) 171-185
  PubMedGoogle Scholar
• 59 Lahtela J T, Arranto A J, Sotaniemi E A. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects.  Diabetes. 1985;  34(9) 911-916
  CrossrefPubMedGoogle Scholar
• 60 Dong B, Saha P K, Huang W et al.. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease.  Proc Natl Acad Sci U S A. 2009;  106(44) 18831-18836
  CrossrefPubMedGoogle Scholar

Carol J SorokaPh.D. 

Department of Internal Medicine–Digestive, Yale University School of Medicine

333 Cedar Street/1080 LMP, P.O. Box 208019, New Haven, CT 06520-8019

Email: carol.soroka@yale.edu